Analyst Price Target is $0.18
▲ +188.78% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for MediPharm Labs in the last 3 months. The average price target is $0.18, with a high forecast of $0.25 and a low forecast of $0.10. The average price target represents a 188.78% upside from the last price of $0.06.
Current Consensus is
The current consensus among 1 polled investment analysts is to buy stock in MediPharm Labs. This rating has held steady since April 2022, when it changed from a Hold consensus rating.
MediPharm Labs Corp., a pharmaceutical company, produces and sells pharmaceutical-quality cannabis oil and concentrates, and advanced derivative products in Canada, Australia, Germany, and internationally. It formulates, processes, packages, and distributes cannabis extracts and advanced cannabinoid-based products. The company also provides GMP flower sourcing, packaging, and distribution services. MediPharm Labs Corp. was founded in 2015 and is headquartered in Barrie, Canada.